SCHEMBL1484444

SCHEMBL1484444

O=C(O)C(CC(F)(F)F)C(=O)OC(Cc1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CPA1 P15085 1/20 0.46
CYP1A2 P05177 1/20 0.41
PPARG P37231 5/20 0.41
PPARA Q07869 4/20 0.41
SRR Q9GZT4 2/20 0.40
EPHX1 P07099 1/20 0.40
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
SLC1A1 P43005 1/20 0.40
ALPI P09923 1/20 0.39
PKM P14618 1/20 0.39
PTGS1 P23219 1/20 0.39
XIAP P98170 1/20 0.39
SLC7A5 Q01650 1/20 0.39
MDM2 Q00987 1/20 0.38
CHRM1 P11229 1/20 0.38
BACE1 P56817 1/20 0.38
ACE P12821 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11704440 0.78 CTSB (0.46) CYP1A2ACE
SCHEMBL9470508 0.76 CHRM1 (0.43) CYP1A2PPARGPPARASRREPHX1
SCHEMBL3206845 0.76 CYP1A2 (0.46) CPA1CYP1A2SRREPHX1SLC1A3
SCHEMBL27726511 0.74 EPHX1 (0.52) CPA1CYP1A2SRREPHX1ALPI
SCHEMBL9067637 0.74 EPHX1 (0.52) CPA1CYP1A2SRREPHX1ALPI
SCHEMBL11845837 0.74 EPHX1 (0.52) CPA1CYP1A2SRREPHX1ALPI
SCHEMBL11347968 0.74 PPARG (0.42) CYP1A2PPARGPPARASRREPHX1
Hydrochloric Acid SCHEMBL11845834 0.73 EPHX1 (0.50) CPA1CYP1A2SRREPHX1ALPI
SCHEMBL1484442 0.72 ALDH1A1 (0.50)
SCHEMBL7655431 0.72 EPHX1 (0.58) CYP1A2SRREPHX1ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078256-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2013-03-28 US disclosed
US-8334295-B2 Pyrimidine derivatives as HIV reverse transcriptase inhibitors KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-12-18 US disclosed
US-20110076276-A1 Novel HIV reverse transcriptase inhibitors GILEAD SCIENCES, INC. (US) 2011-03-31 US disclosed
EP-2167476-A2 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS Korea Research Institute Of Chemical Technology (KR) 2010-03-31 EP disclosed
WO-2009005674-A2 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110076276-A1 Novel HIV reverse transcriptase inhibitors POLR2E, POLR1E, POLR2H CPA1 937/4885CYP1A2 3032/4885PPARG 4125/4885
US-20130078256-A1 NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS POLR2E, POLR1E, POLR2H CPA1 937/4885CYP1A2 3032/4885PPARG 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.